<SEC-DOCUMENT>0001213900-17-005422.txt : 20170517
<SEC-HEADER>0001213900-17-005422.hdr.sgml : 20170517
<ACCEPTANCE-DATETIME>20170517165710
ACCESSION NUMBER:		0001213900-17-005422
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20170515
FILED AS OF DATE:		20170517
DATE AS OF CHANGE:		20170517

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			O'Loughlin Steve
		CENTRAL INDEX KEY:			0001615840

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		17852287

	MAIL ADDRESS:	
		STREET 1:		955 HARTMAN RUN ROAD
		CITY:			MORGANTOWN
		STATE:			WV
		ZIP:			26507
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>f3051517oloughlin_actinium.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2017-05-15</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001388320</issuerCik>
        <issuerName>Actinium Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>ATNM</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001615840</rptOwnerCik>
            <rptOwnerName>O'Loughlin Steve</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ACTINIUM PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>275 MADISON AVENUE, 7TH FLOOR</rptOwnerStreet2>
            <rptOwnerCity>NY</rptOwnerCity>
            <rptOwnerState>NY</rptOwnerState>
            <rptOwnerZipCode>10016</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>VP, Finance and Corporate Dev.</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Options to purchase common stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.79</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2015-10-01</value>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2025-10-01</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>100000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Options to purchase common stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.99</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2016-04-14</value>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2026-04-14</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>50000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Options to purchase common stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.39</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2017-03-14</value>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2027-03-14</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>100000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">A total of 28% of the options will vest one year from the grant date, and the remaining 72% shall vest in equal increments of 2% per month of the initial option grant over the following three year period.</footnote>
        <footnote id="F2">Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant.</footnote>
        <footnote id="F3">Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. In addition, 25,000 options are subject to cancellation based on the obtainment of certain milestones.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Steve O'Loughlin</signatureName>
        <signatureDate>2017-05-17</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
